Vishal Khairnar
Consultant Synaptimmune Therapeutics
Seminars
Thursday 11th September 2025
Conditionally Active CD2 Co-Stimulatory DLL3 T-Cell Engager With Increased Efficacy & Minimal Cytokin Release Compared to TarlatamabTM in Small Cell Lung Cancer & Neuroendocrine Tumors
10:30 am
- Built-in CD2 Costimulation in DLL3 T cell engager (TCE) enhances CD3 synapse formation and signaling to increase tumor killing in Small Cell Lung Cancer (SLC)
- Conditional Activation of TCE only in the presence of antigen engagement overcomes cytokine release syndrome associated with conventional TCEs
- Shows increased efficacy and safety for SLC tumor killing in vitro and in humanized SLC tumor models compared to approved TCE, TarlatamabTM
